Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 71 entries
View as:

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT05055908 Org: User:
Start: 10/01/21 End: 09/14/27 Due: 09/14/28

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05055999 Org: User:
Start: 04/01/19 End: 09/01/21 Due: 09/01/22

Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05055947 Org: User:
Start: 04/01/19 End: 09/14/21 Due: 09/14/22

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

Phase: N/A Priority: Normal
NCT ID: NCT06634667 Org: User:
Start: 11/30/24 End: 04/30/27 Due: 04/30/28

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06109558 Org: User:
Start: 12/31/23 End: 07/30/27 Due: 07/30/28

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

Phase: N/A Priority: Normal
NCT ID: NCT04322591 Org: User:
Start: 03/24/20 End: 03/24/25 Due: 03/24/26

Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients

Phase: N/A Priority: Normal
NCT ID: NCT05129462 Org: User:
Start: 08/05/18 End: 10/01/21 Due: 10/01/22

Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06828757 Org: User:
Start: 05/01/25 End: 04/30/27 Due: 04/30/28

Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05584267 Org: User:
Start: 12/25/22 End: 12/31/26 Due: 12/31/27

Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04997382 Org: User:
Start: 08/17/21 End: 01/31/24 Due: 01/31/25

SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04937972 Org: User:
Start: 07/01/21 End: 06/01/25 Due: 06/01/26

To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05805267 Org: User:
Start: 09/20/22 End: 03/25/23 Due: 03/25/24

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05991206 Org: User:
Start: 12/25/23 End: 08/01/26 Due: 08/01/27

The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06477055 Org: User:
Start: 10/01/24 End: 06/15/27 Due: 06/15/28

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Phase: N/A Priority: Normal
NCT ID: NCT05379803 Org: User:
Start: 05/01/22 End: 03/31/25 Due: 03/31/26

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06183762 Org: User:
Start: 01/01/20 End: 06/30/25 Due: 06/30/26

A Non-interventional Study With Advanced Lung Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05984017 Org: User:
Start: 07/01/21 End: 12/31/25 Due: 12/31/26

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04324151 Org: User:
Start: 03/24/20 End: 03/24/25 Due: 03/24/26

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04322890 Org: User:
Start: 04/16/20 End: 12/24/27 Due: 12/24/28

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Phase: N/A Priority: Normal
NCT ID: NCT06497543 Org: User:
Start: 10/01/24 End: 04/30/26 Due: 04/30/27

Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction

Phase: N/A Priority: Normal
NCT ID: NCT06604351 Org: User:
Start: 09/15/24 End: 05/31/29 Due: 05/31/30

Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

Phase: N/A Priority: Normal
NCT ID: NCT06073938 Org: User:
Start: 09/20/22 End: 06/30/25 Due: 06/30/26

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04324125 Org: User:
Start: 03/24/20 End: 03/24/25 Due: 03/24/26

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04951947 Org: User:
Start: 06/01/23 End: 06/01/25 Due: 06/01/26

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06196814 Org: User:
Start: 10/01/24 End: 02/01/27 Due: 02/01/28